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Abstract 
Most surveys show that, other than among men who inject drugs and have a history of 
homosexual contact, the prevalence of HIV infection among injecting drug users (IDUs) 
in Australia is about 2%. Rates of needle sharing have also declined greatly in the last 
decade, although the high prevalence and incidence of hepatitis C infection suggest that 
existing strategies have not yet brought this epidemic under control. 
Harm reduction has been the major Australian approach to the reduction of blood borne 
viral infections (BBVIs) in IDUs. Harm reduction strategies include needle distribution 
schemes, drug substitution therapies and education about safe administration practices. 
Importantly, with IDUs as with gay men, the infected and affected communities have 
been brought into partnership with health educators, researchers and policy makers.  
This paper will review Australia’s approach to the prevention of BBVI in IDUs and the 
effectiveness of current strategies. I will argue that while HIV/AIDS among heterosexual 
IDUs appears to have been successfully prevented, international experiences of rapidly 
emerging epidemics demonstrate there is little room for complacency. Moreover, 
reducing the incidence of hepatitis C and hepatitis B among IDUs remains a major 
challenge.  
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Doing harm reduction is contentious. There are debates about which harms to which 
people should be reduced, and how these can be measured, and whether abstinence based 
policies reduce harm more effectively than those which focus on safer behaviour (Hawks 
& Lenton, 1998). In Australia, however, there has been some consensus  about 
approaches to reducing HIV/AIDS in injecting drug users. Harm reduction strategies, 
which were understood to be those which decreased the prevalence of behaviours which 
caused the virus to be transmitted although they might not reduce injecting or other drug 
use, have been part of national HIV/AIDS policy from the outset. Australia has limited 
the spread of HIV/AIDS in IDUs by adopting harm reduction policies. It is a different 
story with the other BBVIs, hepatitis  C and hepatitis B.  
In this paper I will briefly overview the Australian epidemics of HIV and hepatitis C as 
they affect IDUs. I will then discuss the role of some of the major harm reduction 
strategies - needle and syringe provision, drug treatment and education and prevention 
programs - in reducing the harms associated with these epidemics. I will outline what I 
consider to be some of the major threats to the current position – the reduction in support 
for some programs, the situations in prisons and some cautionary tales from other 
countries. I will conclude by briefly considering the ‘forgotten’ epidemic – hepatitis B.  
The epidemics 
The success of harm reduction strategies in preventing an epidemic of HIV/AIDS among 
heterosexual IDUs in Australia has been evident for some years. The 1999 annual 
surveillance report on BBVIs in Australia, for example, reports that approximately 8% of 
HIV diagnoses in Australia have been among people who inject drugs, but that about half 
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of these are among men who also report a history of homosexual contact. The same 
report notes that HIV prevalence was less than 0.6% among female and male IDUs seen 
at sexual health centres between 1993 and 1998, and less than 3% among heterosexuals 
attending needle and syringe programs (NSPs) (NCHECR, 1999). This rate has remained 
largely unchanged since the first NSP survey in 1995. That this is an exceptional figure 
can be seen by comparison of rates of infection in comparable countries in Europe, in the 
United States and our neighbours in South East Asia. 
Hepatitis C is, of course, a very different epidemic with an estimated 200 000 infections, 
compared to an estimated total of 17 600 HIV infections. More than 125 000 people have 
been notified with hepatitis C since antibody testing became available in 1990, and there 
are now around 18 000 – 20 000 notifications a year (NCHECR, 1999). Eighty percent of 
infections are considered to be as a result of injecting drugs (Lowe & Cotton, 1999).  
While there have been HIV/AIDS National Strategies since 1989, the hepatitis C virus 
was not identified until 1989, and the blood supply not secured until 1990 when a 
screening test became available. A National Hepatitis C Action Plan was developed in 
1994 and a Nationally Coordinated Approach to Education and Prevention was put in 
place in 1995. Hepatitis C was included as a ‘Related Disease’ in the 1996-97 Third 
National HIV/AIDS Strategy. The National Hepatitis C Action Plan has recently been 
reviewed and a detailed report made. One of the responses to this report has been a 
decision that there will be a National Hepatitis C Strategy, linked to, but separate from, 
the next HIV/AIDS Strategy.  
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The determinants of both HIV/AIDS and hepatitis C epidemics are background virus 
prevalence, viral infectiousness and the existence of behaviour that permits spread but 
hepatitis C is more infectious than HIV which means that smaller amounts of blood can 
transmit the infection (Crofts, Aitken & Kaldor,1999). While enough IDUs have stopped 
sharing needles to limit the spread of HIV, environmental contamination with infected 
blood during an injecting occasion may be enough to transmit hepatitis C, and these are 
contaminations of which the average IDU may be largely unaware (Carruthers, 1999). 
And finally, as Crofts et al. (1999) succinctly state,  
“The difference in incidence comes down to the force of numbers … An IDU 
sharing a needle used by another IDU of unknown infection status is at somewhere 
between 150 and 800 times higher risk of infection with HCV than HIV” (p. 220)  
The review of the National Hepatitis C Action Plan noted that an infrastructure of NSPs, 
methadone programs, and education programs for IDUs existed by the time HCV was 
identified, and that community based organisations – drug users’ groups and more 
recently hepatitis C councils – have been funded in most jurisdictions. Despite these 
programs, however, enough blood to blood contact between IDUs is occurring for the 
epidemic to be maintained. This seems to suggest that education and prevention programs 
has not been sufficiently effective. The review also, however, noted that hepatitis C had 
not been accorded sufficient priority for a number of reasons including that it is a disease 
poorly understood by the general community (Lowe & Cotton, 1999).  
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Needle and syringe programs 
Australia is justifiably famous around the world for its HIV/AIDS prevention programs. 
The corner stone of our endeavours to reduce BBVIs among IDUs has been programs 
which distribute sterile injecting equipment to drug injectors. The first pilot (and illegal) 
NSP in Australia was established in November 1986, with government funded NSPs set 
up from early 1987, first in NSW where there was perceived to be most need, but rapidly 
thereafter in other states (Wodak 1995). The first Western Australian NSP, for example, 
was set up in July 1987 (Loxley et al, 1991). NSPs are not the only source of sterile 
injecting equipment, however, and pharmacy sale of needles and syringes is an additional 
important aspect of the needle distribution program. Very few if any programs now insist 
on one to one exchange (Burrows, 1998) but exchange  can be facilitated by providing 
free equipment in exchange for used equipment, and charging at a cost-recovery rate for 
non-exchanged equipment. 
There is ample evidence, both Australian and international, that NSPs are effective in 
preventing HIV infection without being associated with a rise in drug use (Hurley, Jolley 
& Kaldor, 1997; Lurie, 1997). In his evaluation of the National HIV/AIDS Strategy 
1993/94 to 1995/96, Feachem (1995) estimated that 3000 cases of HIV were avoided in 
Australia in 1991 through the operation of NSPs, and that the savings in treatment costs 
due to the prevention of HIV infection more than offset the operating costs of the 
program. The most plausible assumptions suggested that this involved a saving of some 
$267 million in 1991.  
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The hepatitis C epidemic, however, far from being prevented, is being maintained by 
blood to blood contact, primarily through shared injecting equipment, and a central 
requirement for reducing it is to expand NSPs to meet distribution targets based on IDUs 
always using sterile injecting equipment. The current uncertain support of NSP programs 
by State and Territory governments, however, is a concern. ANCARD1, in their review of 
the Third National HIV/AIDS Strategy, pointed out that there had been steep rises in the 
number of people injecting drugs, but no uncapped funding to meet the exponentially 
increasing demand for injecting equipment:  
“It will be difficult, if not impossible, for the States and Territories to continue to 
fund needle and syringe programs to the level required without compromising other 
programs” (ANCARD, 1999 p. 53).  
This difficulty can be demonstrated in Western Australia. There has been a recent 
controversy over perceived shortfalls in State funding for needle exchange, which has 
only been resolved in the short term. While 2/3 of all WA injecting equipment is sold 
through pharmacies rather than given away, not all WA injectors can access sterile 
equipment for every injection. In a  local study, injectors who purchased injecting 
equipment in pharmacies were asked to complete short questionnaires attached to the 
FitPacks2 that they bought. Over a third said that they had shared a needle because they 
did not have enough money to buy a FitPack, and 40% reused their own equipment, often 
to save money (Lenton et al., in press).  
                                                 
1 Australian National Council on AIDS and Related Diseases 
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WA is not alone in finding difficulty in funding NSPs, and lack of political support for 
increased funding despite rises in injecting related to the increased availability of heroin 
appears to have been developing in Australia. There also appears be a political reality 
about epidemics the community is and is not prepared to tolerate. This point will be 
addressed below.  
Injecting equipment provision is not the only element in the Australian approach to the 
reduction of BBVIs in IDUs. The expansion of drug treatment places, particularly in 
methadone maintenance treatment (MMT) has been another vitally important aspect of 
the approach.  
It is clear that MMT assists in the reduction of HIV-risk behaviour and can reduce the  
incidence of HIV infection. Participation in MMT is related to less frequent injecting, less 
frequent sharing, fewer sharing partners and lower HIV seroprevalence (Darke,1992). It 
remains to be seen whether alternative pharmacotherapies for opiate dependence (LAAM, 
buprenorphine, naltrexone, tincture of opium and slow-release oral morphine, all of 
which are currently being trialled) will do as well. It appears that Australians are not 
going to know, at least for some years, whether the provision of heroin as a treatment 
modality would do as well as or better than methadone, despite encouraging signs from 
the Swiss heroin trials. 
The question of whether MMT also reduces the risk of hepatitis C has not been resolved: 
one difficulty is that the rate of hepatitis C infection among methadone clients is usually 
                                                                                                                                                 
2 Pack of needles and syringes in rigid disposable container. At the time of the study all injecting 
equipment was sold to drug users in this form.   
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so high (Selvey et al, 1997) that demonstrating prevention can be difficult. It should, 
however, be effective among those who are not already infected. To state the obvious, if 
MMT reduces the prevalence of injecting, the occasions on which there is a risk of HCV 
transmission are reduced. Since hepatitis C prevalence is closely linked to duration of 
injecting (Loxley et al., 1995) methadone and other treatments would be more effective 
against hepatitis C if they were undertaken earlier in the injector’s career. The Federal 
Government’s recent  Tough on Drugs Diversion Program which will divert first time or 
minor drug offenders to compulsory assessment and referral to treatment or education is 
an early intervention approach along these lines and it will be important to monitor it 
carefully to see whether it is having a hepatitis C prevention effect.   
Education and prevention programs 
The development of appropriately targeted education and prevention programs is another 
important aspect of HIV/AIDS strategies. Education of drug users about safe 
administration has undoubtedly been effective: rates of needle sharing have fallen since 
HIV/AIDS first became a concern, and in the four annual national NSP surveys, the rates 
of those who admitted using a needle after someone else in the previous month were 31% 
in 1995, 28% in 1996, 14% in 1997 and 18% in 1998. Feachem (1995) commented that it 
was highly probable that not only NSPs, but also peer education and community 
development were responsible for the low prevalence of HIV/AIDS among IDUs in 
Australia.  
Once again, however, we should be careful not to be complacent. Partnerships between 
the IDU community and health educators, researchers and policy makers are supposedly 
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as important in the fight against HIV infection within the IDU community as within the 
gay community, and funding drug user organisations has been part of the approach. It has 
been pointed out, however, that while many funded drug users organisations could have 
played a crucial role in peer education, resource production, research facilitation and 
policy advice, most were only funded to provide peer-based needle exchange. This hardly 
allowed for the optimisation of their role although with adequate support, training and 
funding, drug users’ groups could play a significant role as the consumer health and 
rights organisations for the IDU community (Moore,1995).  
The hepatitis C epidemic has heightened and focused these concerns. The review of the 
National Action Plan received many submissions outlining concerns about the way that 
the partnership approach was played out in real life, and recommended a thorough review 
and refinement of existing strategies for participation of representatives of affected 
communities in policy and decision making at Commonwealth, State and Territory levels 
(Lowe & Cotton, 1999). A number of other recommendations about building the capacity 
of community organisations to represent affected communities were also made, including 
the need to extend the focus. It has been argued that these partnership must include  
“… current and past drug users, those who are just beginning to inject, and those 
who have left it far behind. … we have organisations such as the hepatitis C 
councils, and the AIDS epidemic has left us with … injecting drug user groups …  
which provide us with links into the injecting community … but the partnership 
must extend beyond this and into the wider community where past injecting drug 
users reside” (Orr & Leeder, 1998, p. 193). 
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Prisons 
One of the threats to the stability of the low prevalence of HIV/AIDS among IDUs in 
Australia is the situation in our prisons. Injecting drug use is the main risk factor for HIV 
infection among prisoners (Seamark et al., 1997) but there is little harm reduction beyond 
some education in most Australian prisons. There is, however, plenty of evidence of risk 
behaviour. Dolan et al. (1998) reported that around 30% of prisoners inject drugs, 20% 
tattoo themselves and up to 10% engage in unprotected anal sex. Two studies found that 
HIV positive inmates were significantly more likely to inject and engage in sex than 
inmates who were uninfected or unsure. Needle sharing is common and, because needles 
are very difficult to come by, is different to sharing in the community which is primarily 
between close friends and lovers. In prisons, numerous strangers may share one needle 
(Dolan et al., 1998). 
Dolan and Wodak (1996) have suggested that the extent of the transmission of HIV and 
other BBVIs occurring in prisons has been underestimated. They developed a 
mathematical model of HIV incidence in NSW prisons in 1993 and estimated that 
between 38 and 152 inmates were infected each year (Dolan et al, 1998).  
These findings suggest that prisons should look carefully to policies which might reduce 
the rate of injecting risk behaviour. Prison methadone maintenance treatment (PMMT) is 
clearly one such. An international review of PMMT found that although there was no 
direct evidence that PMMT would reduce HIV transmission, there was evidence that it 
reduced injecting and sharing, and therefore likely to reduce transmission (Dolan & 
Wodak, 1996). 
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There are now some limited programs in NSW, Queensland, South Australia and Victoria 
some of which are under evaluation (Dolan, 1999) but there is considerable scope for 
expansion. Current approaches to the diversion of drug users away from custodial 
sentences also clearly have the potential to reduce the transmission of blood borne viruses 
in prisons, and evaluations should investigate that aspect of these programs. 
In terns of hepatitis C in prisons, one estimate has been that 80% of NSW prisoners have 
chronic hepatitis  C. Cases of contracting the disease within prison have been proven. 
Being in prison is a risk factor arising not only from intravenous drug use but from 
activity like tattooing using non-sterile equipment, sexual assaults which often involves 
drawing blood, other violence and self harm (Haber, 1999). 
Rapidly emerging epidemics 
Another concern is that of rapidly emerging HIV/AIDS epidemics. There are two 
Canadian epidemics which have been used as examples of what could happen in a 
country like Australia which has good NSP coverage and low HIV/AIDS seroprevalence; 
there is sufficient similarity between these epidemics and the situation in Sydney to 
suggest that Australians should not become complacent about low prevalence of 
HIV/AIDS among IDUs (Wodak, 1999).  
The first example is Vancouver which introduced a needle exchange program (NEP) in 
1988. Vancouver’s NEP is the largest in North America, in 1997 exchanging over 2 
million needles per year, and was, until recently, considered to be a major factor 
accounting for Vancouver’s low HIV prevalence rate, which at the time of the 
introduction of the program, was estimated to be 1 –2% among IDUs. In 1993 the NEP 
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was evaluated by the US Centres for Disease Control and Prevention and ranked in the 
top three in North America in terms of number of syringes exchanged and returned, 
estimated proportion of IDUs reached, and number of client referrals to drug treatment 
and support services (Strathdee et al, 1997).  
Since September 1994  there has, however, been a rapid increase in HIV infection with 
the proportion of IDUs testing HIV seropositive rising from 2 to 7% in an 18 month 
period. A new cohort study which recruited over 1000 IDUs, most of whom had attended 
the NEP, was initiated in 1996 to study this increase, and baseline HIV prevalence was 
found to be 23.2%. After 8 months of follow-up the preliminary estimate of HIV 
incidence was between 16.5 and 18.6 per 100 person-years. It was concluded that these 
results “were consistent with an on-going and serious outbreak of HIV infection among 
IDU in Vancouver” (Strathdee et al, 1997, p. F63). The researchers also believed that 
needle sharing in this population was normal, and that little if any behaviour change 
resulted from a HIV-positive test result.  
These findings have been interpreted by some as evidence that NEPs do not work 
although this is contrary to the bulk of the literature:  
“In cities were NEP is part of a comprehensive program that includes HIV testing, 
counselling, education and drug treatment options, HIV incidence and associated 
risk behaviours have declined significantly over time” (Strathdee et al, 1997, p. 
F63).  
In Vancouver, however, access to drug and alcohol treatment, methadone maintenance 
and counselling services remained inadequate (Strathdee et al, 1997). The researchers 
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considered than a shift from heroin to cocaine use, with its associated increased 
frequency of injecting, might have been an important factor in Vancouver’s escalating 
HIV prevalence and incidence, since cocaine injecting was more frequent among HIV 
positive IDUs, and appropriate treatment for cocaine use was more limited than opiate 
treatment. They concluded that NEP is a necessary but not sufficient element of HIV 
prevention among IDUs: other complementary strategies are also needed including 
treatment, education, and social services.  
The other Canadian example centres upon Montreal. Bruneau et al. (1997) found that 
IDUs who attended the Montreal NEP were 2.2 times as likely to be HIV positive at 
baseline than non-attenders, and 1.7 times as likely to seroconvert during 15 months 
follow-up. Although these findings, like those in the Vancouver experience, have been 
used to argue that needle exchange does not work, it is more likely that unusual local 
conditions in Montreal had attracted particularly high-risk IDUs to the NEP, bringing 
with them higher seroconversion rates (Lurie, 1997). The major conclusion from the 
Montreal study was that what was needed “to reduce the terrible toll” of HIV among 
Montreal IDUs was not less needle exchange but more (Bruneau et al, 1997). 
As I noted earlier, the examples of Vancouver and Montreal have been used as a 
cautionary tale in Australia particularly as  the shift to cocaine injecting identified in 
Vancouver, is becoming apparent in Sydney (MacDonald, McKetin et al, 1999). Other 
threats to the stability of HIV prevalence among IDUs are associations between social 
disadvantage and HIV seropositivity: in Vancouver, for example, what was termed 
‘unstable housing’ and low education were the only two independent predictors of HIV-
positive serostatus. In Sydney, cocaine injecting has been observed among sex workers 
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and other socially disadvantaged groups. It remains to be seen whether cocaine injecting 
will spread to other parts of the city bringing with it an increased risk of BBVIs in IDUs.  
Hepatitis B: the ‘forgotton’ epidemic  
Hepatitis B was identified long before HIV/AIDS and hepatitis C but, perhaps because of 
this, has never really assumed the same importance in the mind of injectors, the 
community and, possibly, health professionals. This is not a trivial disorder although 
comprehensive data on incidence, prevalence, morbidity and mortality in Australia is 
incomplete (Kaldor et al, 1996). 
It is almost 20 years since the National Health and Medical Research Council called for 
all IDUs to be vaccinated against hepatitis B because of their high risk status (Gust, 
1992), but it is clear that this has not occurred. As an example, in a recent study about 
blood borne virus testing and vaccination  among IDUs, undertaken by myself and 
colleagues, 70% of 200 IDUs had been tested for hepatitis B but only 24% had been 
vaccinated although many of the non-vaccinated had been found to be seronegative. 
Many of those who had not been vaccinated, moreover, reported that had never heard of 
vaccination or been offered it. Some did not understand why IDUs were at risk of 
hepatitis B, or why they should be vaccinated. Some were concerned about the cost of 
vaccination  when the experience of those who had been vaccinated demonstrated that 
free vaccine was available (Loxley et al., 2000). 
It seems extraordinary that when so many of the respondents in this study had been tested 
because they were IDUs, so few had been vaccinated, particularly when many of these 
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had received a negative hepatitis B test. Clearly, opportunities for prevention of this 
disease had been squandered. 
Conclusion  
If HIV/AIDS had exploded among Australian IDUs as it did in other countries, it could 
have leapt into the general community with disastrous results. That it did not was partly 
because of far sighted and non-partisan action on the part of politicians, and their 
preparedness to put into place harm reduction strategies which, it could be supposed, the 
community would have difficulty, at least at first, in understanding or supporting.  
Hepatitis C is different. Not as terrible as HIV/AIDS, but far more prevalent. Many will 
not die of it, but the lives they will live with it will be diminished and difficult. They will 
not be as productive as healthy people. There will be many with severe liver disease and 
our public health systems may find themselves having to make decisions about who 
should and who should not be eligible for liver transplants. 
As I noted at the outset, as long as the major concern was HIV/AIDS there was less 
contention about harm reduction in the area of injecting drug use and blood borne viruses 
than in some other areas. Arguably, the non-drug using community could be convinced 
that almost any strategy, not matter what it did, or how much it cost, was the right 
strategy if it reduced the risk to them. But is that still true? Support for harm reduction 
appears to be waning, and the rhetoric of ‘mutual obligation’ is taking over. It is hard to 
avoid the conclusion that our political decision-makers do not care about hepatitis C in 
the same way as they did about HIV/AIDS, because the general community is not at the 
same risk.  
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In these circumstances, it is perhaps not surprising that budgets for needles and syringes 
have been capped and show no signs of expanding. It may not be surprising that hepatitis 
C flourishes in prisons but to date the response has been little more than tokenistic. It may 
not be surprising that Australians have a universal hepatitis B vaccination policy for 
infants and pre-adolescents, but IDUs are not told that a vaccine is available.   
Perhaps one of the most encouraging recent moves has been the recognition of the need 
for a National Hepatitis C Strategy, which is now being drafted. Not only because 
hepatitis C is a different disease which needs different strategies, but because it is 
important to name it. As long as hepatitis C was lost under the rubric of ‘related diseases’ 
it was easy to conceive of it as secondary to the main disease – HIV/AIDS.  
For Australian IDUs the main disease is hepatitis C. The community should put as much 
effort into reducing the harm of hepatitis C, as it did into preventing IDUs – and 
themselves – from becoming infected with HIV/AIDS.  
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